A Phase I Study of LAG525 and PDR001 in Patients with Advanced Cancers

Full Title

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Purpose

The purpose of this study is to determine the best dose of the combination of two investigational drugs in people with advanced cancers: LAG525 and PDR001. LAG525 works by blocking a protein called LAG-3, while PDR001 blocks a protein called PD-1. Both LAG-3 and PD-1 often prevent cancer-fighting immune cells from working properly, so inhibiting their activity could boost the power of the immune system to attack cancer cells.

Patients in this study will either receive LAG525 alone or LAG525 with PDR001. Both drugs are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced cancer that has continued to grow or came back despite prior therapy.
  • At least 2 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexandra Snyder Charen at 646-888-5122.

Protocol

15-185

Phase

I/II

Co-Investigators

Locations